Adoption of the 275-Patient Buprenorphine Treatment Waiver for Treating Opioid Use Disorder: A State-Level Longitudinal Analysis

Abstract

Background: Increasing access to buprenorphine treatment is a critical tool for addressing the opioid epidemic in the United States. In 2016, a federal policy change allowed physicians who meet specific requirements to treat up to 275 concurrent buprenorphine patients. This study examines state-level measures of buprenorphine treatment supply over 21 months since this policy change and estimates associations between the supply of 275-patient waivers and state characteristics.

Methods: Monthly state-level measures of the number of physicians holding the 275-patient waiver per 100,000 residents were constructed from September 2016 to May 2018 using the Drug Enforcement Agency's Controlled Substance Act database. State characteristics were obtained from publicly available sources. Mixed-effects regression models were estimated to examine change over time.

Results: During the 21-month period, the number of physicians waivered to treat 275 patients increased from 153 to 4009 physicians. The mean supply of 275-patient physicians per 100,000 state residents significantly increased from 0.07 (SD = 0.21) in September 2016 to 1.43 (SD = 1.08) in May 2018 (t = −9.84, df = 50, P < .001). The final mixed-effects regression model indicated that Census division and the preexisting supply of 100-patient waivered physicians were correlated with the rate of growth in 275-patient waivers over the study period.

Conclusions: Although uptake of the 275-patient waiver has exceeded initial projections, growth is uneven across the United States. Unequal patterns of growth pose a challenge to efforts to increase treatment availability as a means of addressing the opioid epidemic.

Keywords

Buprenorphine DATA 2000 opioid use disorder treatment

Get full access to this article

View all access options for this article.

References

Martins

, Sarvet

, Santaella-Tenorio

, . Changes in US lifetime heroin use and heroin use disorder: prevalence From the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry. 2017;74(5):445455.

Rudd

, Aleshire

, Zibbell

, Gladden

. Increases in drug and opioid overdose Deaths-United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–1382.

Kandel

, Hu

, Griesler

, Wall

. Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances. Drug Alcohol Depen. 2017;178:501–511.

O'Donnell

, Halpin

, Mattson

, Goldberger

, Gladden

. Deaths involving fentanyl, fentanyl analogs, and U-47700 - 10 states, July-December 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1197–1202.

Han

, Compton

, Jones

, Cai

. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003-2013. JAMA. 2015;314(14):1468–1478.

Kolodny

, Courtwright

, Hwang

, . The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36(1):559–574.

Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.

Winkelman

TNA

, Chang

, Binswanger

. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.

Becker

, Sullivan

, Tetrault

, Desai

, Fiellin

. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94(1–3):38–47.

10.

Wilens

, Biederman

, Bredin

, . A family study of the high-risk children of opioid- and alcohol-dependent parents. Am J Addict. 2002;11(1):41–51.

11.

Bukten

, Skurtveit

, Gossop

, . Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction. 2012;107(2):393–399.

12.

Marsch

. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93(4):515–532.

13.

Florence

, Zhou

, Luo

, Xu

. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–906.

14.

Rhyan

. The potential societal benefit of eliminating opioid overdoses, deaths, and substance use disorders exceeds $95 billion per year. https://altarum.org/sites/default/files/uploaded-publication-files/Research-Brief_Opioid-Epidemic-Economic-Burden.pdf. 2017. Accessed February 14, 2018.

15.

Larochelle MR , Bernson

, Land

, . Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018;169(3):137–145.

16.

Nielsen

, Larance

, Degenhardt

, Gowing

, Kehler

, Lintzeris

. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;(5):CD011117.

17.

Nielsen

, Larance

, Lintzeris

. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA. 2017;317(9):967–968.

18.

Mattick

, Breen

, Kimber

, Davoli

. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.

19.

, Zhu

, Swartz

. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127.

20.

Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS): 2005-2015. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-91, HHS Publication No. (SMA) 17-5037. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.

21.

Collins

, Koroshetz

, Volkow

. Helping to end addiction over the long-term: The research plan for the NIH HEAL Initiative. JAMA. 2018;320(2):129–130.

22.

Jones

, Campopiano

, Baldwin

, McCance-Katz

. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.

23.

Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (Treatment Improvement Protocol #40). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.

24.

Knudsen

, Havens JR , Lofwall MR , Studts

, Walsh

. Buprenorphine physician supply: Relationship with state-level prescription opioid mortality. Drug Alcohol Depend. 2017;173 (Suppl 1):S55–S64.

25.

Altice

, Bruce

, Lucas

, . HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: Results from a multisite study. Jaids-J Acq Imm Def. 2011;56:S22–S32.

26.

Stein

, Pacula

, Gordon

, . Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Milbank Q. 2015;93(3):561–583.

27.

Dick

, Pacula

, Gordon

, . Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff. 2015;34(6):1028–1034.

28.

Knudsen

, Lofwall MR , Havens JR , Walsh

. States’ implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence. Drug Alcohol Depend. 2015;157:36–43.

29.

Andrilla

CHA

, Moore

, Patterson

, Larson

. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. J Rural Health. 2019;35(1):108–112.

30.

Wen

, Hockenberry

, Borders

, Druss

. Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment. Med Care. 2017;55(4):336–341.

31.

Clemans-Cope

, Epstein

, Kenney

. Rapid growth in Medicaid spending on medications to treat opioid use disorder and overdose. https://web.archive.org/web/20170710140634/http://www.urban.org/sites/default/files/publication/91521/2001386-rapid-growth-in-medicaid-spending-on-medications-to-treat-opioid-use-disorder-and-overdose_3.pdf. 2017. Accessed August 24, 2017.

32.

Department of Health and Human Services. 42 CFR Part 8, RIN 0930-AA22, Medication assisted treatment for opioid use disorders. Fed Regist. 2016;81(131):44712–44739.

33.

Substance Abuse and Mental Health Services Administration. Understanding the final rule for a patient limit of 275. https://www.samhsa.gov/sites/default/files/programs_campaigns/medication_assisted/understanding-patient-limit275.pdf. 2016. Accessed July 18, 2018.

34.

Stein

, Sorbero

, Dick

, . Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–1212.

35.

Huhn

, Dunn

. Why aren't physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.

36.

Andrilla

CHA

, Coulthard

, Patterson

. Prescribing practices of rural physicians waivered to prescribe buprenorphine. Am J Prev Med. 2018;54(6S3):S208–S214.

37.

Rosenblatt

, Andrilla

CHA

, Catlin

, Larson

. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23–26.

38.

Stein

, Gordon

, Dick

, . Supply of buprenorphine waivered physicians: The influence of state policies. J Subst Abuse Treat. 2015;48(1):104–111.

39.

Knudsen

. The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: A state-level analysis. J Stud Alcohol Drugs. 2015;76(4):644–654.

40.

Sommers

, Gunja

, Finegold

, Musco

. Changes in self-reported insurance coverage, access to care, and health under the Affordable Care Act. J Am Med Assoc. 2015;314(4):366–374.

41.

Wen

, Druss

, Cummings JR . Effect of Medicaid expansions on health insurance coverage and access to care among low-income adults with behavioral health conditions. Health Serv Res. 2015;50(6):1787–1809.

42.

Feder

, Mojtabai

, Krawczyk

, . Trends in insurance coverage and treatment among persons with opioid use disorders following the Affordable Care Act. Drug Alcohol Depend. 2017;179:271–274.

43.

McKenna

. Treatment use, sources of payment, and financial barriers to treatment among individuals with opioid use disorder following the national implementation of the ACA. Drug Alcohol Depend. 2017;179:87–92.

44.

US Census Bureau. Table 1. Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2018 (NST-EST2018-01). https://www.census.gov/data/datasets/time-series/demo/popest/2010s-state-total.html. 2018. Accessed February 13, 2019.

45.

United States Census Bureau. Census regions and divisions of the United States. https://web.archive.org/web/20150226213756/http://www.census.gov/geo/maps-data/maps/pdfs/reference/us_regdiv.pdf. 2015. Accessed February 26, 2015.

46.

Henry

Kaiser Family Foundation. Status of state action on the Medicaid expansion decision. http://kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. Published 2016. Accessed September 21, 2016.

47.

Henry

Kaiser Family Foundation. Uninsured rates for the nonelderly by age. https://www.kff.org/uninsured/state-indicator/rate×age/?dataView=1&currentTimeframe=1&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. 2019. Accessed February 13, 2019.

48.

Henry

Kaiser Family Foundation. Opioid overdose death rates and all drug overdose death rates per 100,000 population (age-adjusted). https://www.kff.org/other/state-indicator/opioid-overdose-death-rates/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D. 2017. Accessed January 23, 2018.

49.

Henry

Kaiser Family Foundation. Individuals reporting needing but not receiving treatment for illicit drug use in the past year. https://www.kff.org/other/state-indicator/individuals-reporting-needing-but-not-receiving-treatment-for-illicit-drug-use-in-the-past-year/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D#notes. 2017. Accessed December 12, 2017.

50.

Rabe-Hesketh

, Skronkal

. Multilevel and Longitudinal Modeling Using Stata. Vol. 1. 3rd ed. College Station, TX: Stata Press; 2012.

51.

Mitchell

. Interpreting and Visualizing Regression Models Using Stata. College Station, TX: Stata Press; 2012.

52.

Rogers

. Diffusion of Innovations. 5th ed. New York, NY: Free Press; 2003.

53.

Ali

, Teich

, Mutter

. The role of perceived need and health insurance in substance use treatment: Implications for the Affordable Care Act. J Subst Abuse Treat. 2015;54:14–20.

54.

Huhn

, Tompkins

, Dunn

. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug Alcohol Depend. 2017;180:279–285.